6-KThe Wire
Enlivex Ltd. files 6-K
Filed Apr 21, 2026 · 2mo ago · Accession 0001213900-26-045892
Plain English
Enlivex Ltd. announced on April 21, 2026, that it received Clinical Trial Application (CTA) approval from the Danish Medicines Agency (DKMA) for a Phase 2b trial of its Allocetra™ immunotherapy for knee osteoarthritis. This approval allows the company to proceed with its clinical trial in Denmark.
Filing details
- Company
- Enlivex Ltd.
- Ticker
- ENLV
- CIK
- 1596812
- Form type
- 6-K
- Filing date
- Apr 21, 2026
- Report date
- Apr 21, 2026
- Document
- ea028706001-6k_enlivex.htm
- Size
- 28 KB